Abstract:Most radiogenomics studies focused on identifying imaging phenotypes as a surrogate to mirror a pre-selected set of molecular tumor parameters in cancer patients, which may not fully characterize heterogeneous biological processes within the tumor region, thus compromising the power of radiogenomics to determine prognosis and guide treatment. In this study, we developed a radiogenomics framework to synergistically integrate CT radiomics signatures with gene profiles to predict 1-year early recurrence (ER) and overall survival (OS) in patients with esophageal cancer (EC) receiving concurrent chemoradiation (CRT). Forty-nine patients diagnosed with EC who were treated with CRT were included in this study. All patients received CT scan before therapy and 468 radiomics features were extracted from tumor regions using texture analysis. Related tumor samples obtained via endoscopic biopsy were also used for gene profiling (1046 genes) via exome sequencing technology. The Mann-Whitney test was applied to assess the differences of individual radiomics and genomics features between ER and non-ER groups. The 4-fold cross validation method and the least absolute shrinkage and selection operator (LASSO) regression were employed to select optimal features from both imaging and gene features. Radiomics and genomics signatures were then built separately based on selected features. The multivariable logistic regression was used to construct a radiogenomics model via integrating radiomics with genomics signatures. The utilities of the radiomics signature, genomics signature and radiogenomics model in predicting 1-year ER were evaluated by ROC method individually. The Kaplan-Meier and log-rank tests were also used to evaluate their effectiveness in prediction of OS. Ten radiomics features and thirty gene expression levels showed significant differences between ER and non-ER groups. Two radiomics features (LLH_GLCM_corrm, LHH_GLSZM_SZLGE) and four genomics features (DFFA, LOC101060524, chr9: 67183179-67219393, CT45A8) were optimally selected to build the radiomics and genomics signatures separately, whose individual values in predicting 1-year ER equal to an AUC of 0.717 and 0.808, respectively. The radiogenomics model constructed showed an improved predictive value with an AUC of 0.832. Furthermore, the radiomics signature showed no significant value in prediction of OS. Instead, both the genomics signature alone and the radiogenomics model showed a significant predictive capability for OS. A radiogenomics model integrating CT radiomics signature with gene characteristics was established to improve the prediction accuracy of ER and OS in patients with EC, which would direct towards integrative system-based approaches with prognostic implications for personalized RT.

Integrating 18F-FDG PET/CT radiomics and body composition for enhanced prognostic assessment in patients with esophageal cancer

Prediction of Overall Survival and Progression-Free Survival by the 18F-FDG PET/CT Radiomic Features in Patients with Primary Gastric Diffuse Large B-Cell Lymphoma.

A 18F-FDG PET/CT-based Deep Learning-Radiomics-clinical Model for Prediction of Cervical Lymph Node Metastasis in Esophageal Squamous Cell Carcinoma

Body Composition and Radiomics from 18F-FDG PET/CT Together Help Predict Prognosis for Patients with Stage IV Non-Small Cell Lung Cancer.

Positron Emission Tomography-Based Radiomics Features May Be Prognostic Of Outcome In Patients With Esophageal Squamous Cell Carcinoma Treated With Chemoradiation Therapy

A Radiomics Nomogram for Non-Invasive Prediction of Progression-Free Survival in Esophageal Squamous Cell Carcinoma

CT radiomics features of meso-esophageal fat in predicting overall survival of patients with locally advanced esophageal squamous cell carcinoma treated by definitive chemoradiotherapy

Development and validation of a machine learning-based 18F-fluorodeoxyglucose PET/CT radiomics signature for predicting gastric cancer survival

The role of 18F-FDG PET/CT in predicting the pathological response to neoadjuvant PD-1 blockade in combination with chemotherapy for resectable esophageal squamous cell carcinoma

Gastro-Esophageal Cancer: Can Radiomic Parameters from Baseline 18F-FDG-PET/CT Predict the Development of Distant Metastatic Disease?

Prognostic and Incremental Value of Computed Tomography-Based Radiomics from Tumor and Nodal Regions in Esophageal Squamous Cell Carcinoma

Computed Tomography-Based Radiomics Nomogram for Predicting the Postoperative Prognosis of Esophageal Squamous Cell Carcinoma: A Multicenter Study

Innovative Prediction of VEGF Levels and Prognosis in Gastric Cancer Through PET/CT-Based Radiomics

CT-based radiomics for predicting radio-chemotherapy response and overall survival in nonsurgical esophageal carcinoma

CT-based radiomics combined with hematologic parameters for survival prediction in locally advanced esophageal cancer patients receiving definitive chemoradiotherapy

A machine learning approach using 18F-FDG PET and enhanced CT scan-based radiomics combined with clinical model to predict pathological complete response in ESCC patients after neoadjuvant chemoradiotherapy and anti-PD-1 inhibitors

The Role of PET-Based Radiomic Features in Predicting Local Control of Esophageal Cancer Treated with Concurrent Chemoradiotherapy

Contrast-enhanced CT-based radiomic analysis for determining the response to anti-programmed death-1 therapy in esophageal squamous cell carcinoma patients: A pilot study

Predicting response to immunotherapy plus chemotherapy in patients with esophageal squamous cell carcinoma using non-invasive Radiomic biomarkers

The Prognostic Value of Positron Emission Tomography/computed Tomography-Based Parameters in Locally Advanced Esophageal Squamous Cell Carcinoma Treated with Chemoradiation Therapy

A Radiogenomics Framework To Improve Prediction Of Clinical Outcomes In Patients With Esophageal Cancer Treated With Concurrent Chemoradiotherapy